TrialInternational journal of hematology2021

Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.

Charles Chuah et al.PubMed ↗Publisher ↗

No numbers read from the abstract.